I didn't feel taken seriously. I didn't really feel like I had six months to wait.
For years, Michelle Williams carried an illness that medicine had no name for and no remedy to offer — her body failing in ways that specialists dismissed or misread, her future quietly narrowing toward kidney failure. The approval of pegcetacoplan, now known as Empaveli, marks the first time science has offered a genuine answer to IC-MPGN, a kidney disease so rare it touches only a handful of people per million. It is a reminder that the rarest suffering is not the least real, and that persistence — a patient's, a physician's, a researcher's — can eventually bend the arc of a disease once thought untreatable.
- A woman's body was failing for years while doctors attributed her worsening symptoms to stress, costing her time she could not afford to lose.
- Even after reaching a specialized center, the path to diagnosis wound through a false cancer diagnosis and months of chemotherapy that treated the wrong disease entirely.
- IC-MPGN carried a near-certain sentence of end-stage kidney failure within a decade, with no therapy capable of addressing its root cause — only slowing the damage.
- Enrollment in a clinical trial for pegcetacoplan brought rapid, dramatic improvement where years of aggressive treatment had failed.
- The FDA's approval of Empaveli in mid-2025 transforms IC-MPGN from an untreatable condition into one with a viable path to remission for the first time in its known history.
Michelle Williams noticed her blood pressure rising during the pandemic and assumed, as her doctor did, that the pressures of two young children and a home renovation were to blame. But the signals kept coming — swollen feet, bone-deep fatigue, legs that puffed through the night. A referral to a kidney specialist in mid-2023 offered little comfort; she left feeling unseen and was told to return in six months. She knew she couldn't wait.
She referred herself to Cleveland Clinic, where her father-in-law had once received a kidney transplant, sending her records ahead with a letter that simply asked for help. The response was swift and serious: two full days of appointments, urgent biopsies, and an initial finding that pointed toward multiple myeloma. For nearly six months she underwent chemotherapy and immunotherapy — only to see no improvement. Her nephrologist, Dr. Jagmeet Dhingra, refused to accept that answer. A second round of biopsies told a different story: her bone marrow was healthy, but her kidneys were being attacked by complex immune deposits.
The diagnosis was IC-MPGN, a condition so rare that only one to four people per million ever receive it. At the time, no treatment existed that could actually stop it. Steroids and chemotherapy managed symptoms but not the disease itself, and most patients faced kidney failure within a decade — transplants included. 'We were not fixing the problem,' said Dr. Carla Nester, a kidney researcher who has studied the condition. 'It was a horrible prognosis, frankly.'
In late 2024, Dhingra told Williams about a drug in clinical trials called pegcetacoplan. She enrolled in February 2025, and the change was almost immediate — the swelling receded, her energy returned, and she felt, as she put it, like herself again. That June, the FDA approved the drug under the brand name Empaveli, making it the first therapy ever proven to bring IC-MPGN patients into remission. For Williams, and for the small, scattered population living with this disease, the fog has finally begun to lift.
Michelle Williams first noticed her blood pressure climbing in the thick of the pandemic. Two young children, a farmhouse renovation underway, a husband juggling it all—stress seemed like the obvious culprit. Her doctor agreed, suggested some lifestyle tweaks, and didn't sound worried. But the body kept sending signals her mind couldn't ignore.
Her feet swelled so badly she had to buy new shoes. Fatigue settled into her bones. She was waking at night, again and again, to use the bathroom. Her ankles puffed up. Then her legs. The blood pressure kept rising. When her doctor finally referred her to a kidney specialist in June 2023, Williams felt a small spark of hope—someone trained in this, someone who would look closer.
The appointment crushed that hope. The physician assistant she saw barely glanced at the medical records Williams had carefully printed and brought. The advice was generic: lower your blood pressure. No curiosity about why it was so high. No real examination of what might be driving it. She was told to come back in six months. Sitting in her car afterward, Williams felt something break. "I didn't feel taken seriously," she would later say. "I didn't really feel like I had six months to wait."
She didn't wait. In July 2023, Williams referred herself to Cleveland Clinic, where her father-in-law had received a kidney transplant years before. She sent her medical records ahead, along with what she called an impassioned letter: "Please help me, something's wrong." Weeks passed. Then she got a call scheduling two full days of appointments. After a barrage of tests and exams, she and her husband drove home. As they pulled into their driveway, her phone rang. The nephrologist was alarmed by her blood work. He wanted to do biopsies—bone marrow and kidney. "That was kind of scary," Williams said. They turned the car around.
Within 24 hours, both biopsies were done. She answered hundreds of questions designed to narrow down what was happening inside her body. The initial results pointed to multiple myeloma, a blood cancer that can damage kidneys. For nearly six months, Williams endured chemotherapy and immunotherapy. But her symptoms didn't improve. Dr. Jagmeet Dhingra, her nephrologist, found this troubling. "If we are treating the underlying cause and she's not improving, then what else are we looking at?" he said. "It didn't sit right." He kept looking.
A second round of biopsies revealed something different: her bone marrow was actually healthy, but complex immune deposits were accumulating in her kidneys. After ruling out every other possibility, Dhingra arrived at a diagnosis: IC-MPGN, an immune-system-related kidney disease so rare that only one to four people per million are ever diagnosed with it. At the time, there was no specific treatment. The standard approach—steroids, immunosuppressants, chemotherapy—helped some symptoms but didn't slow the disease's progression. Patients typically had about a decade before their kidneys failed completely. Even a transplant only delayed the inevitable, because the underlying condition was never actually treated. "We were not fixing the problem," said Dr. Carla Nester, a kidney researcher at the University of Iowa. "It was a horrible prognosis, frankly."
Williams felt trapped in a fog of medications that either did nothing or made her feel worse. Then, in November 2024, Dhingra called with news about pegcetacoplan, a drug still in clinical trials that showed real promise for IC-MPGN. Williams was nervous but enrolled in February 2025. The change was immediate. "Right away, we saw change," she said. "I was back to my feisty self. I felt like I had freedom back." Six months later, the FDA approved pegcetacoplan under the brand name Empaveli, making it the first medication ever proven to treat IC-MPGN effectively. Patients could finally stop the aggressive therapies that weren't working and move toward actual remission. After more than a year on the medication, Williams' swelling is gone. She takes far fewer drugs. She no longer obsesses over what she eats or how much sleep she gets. "I just feel back to myself again," she said.
Citações Notáveis
If we are treating the underlying cause and she's not improving, then what else are we looking at and what else are we missing?— Dr. Jagmeet Dhingra, nephrologist at Cleveland Clinic
We were not fixing the problem. It was a horrible prognosis, frankly.— Dr. Carla Nester, kidney researcher at University of Iowa
A Conversa do Hearth Outra perspectiva sobre a história
What made her finally push back on that first nephrologist's dismissal?
She was living with progressive symptoms that were getting worse, not better. The swelling, the fatigue, the sleepless nights—these weren't abstract complaints. They were changing her daily life. When someone tells you to wait six months while your body is clearly failing, at some point you stop accepting that answer.
Why did Cleveland Clinic take her seriously when the first doctor didn't?
They had the infrastructure and the culture to actually investigate. Two full days of appointments, hundreds of diagnostic questions, willingness to do biopsies and keep digging even when the first diagnosis didn't explain her symptoms. That's not just better medicine—it's a different approach to the patient entirely.
The multiple myeloma diagnosis was wrong, but did it matter that they found it?
In a way, yes. It got her into the system at a place that wouldn't stop looking. And it bought time for Dhingra to keep questioning why she wasn't improving. If they'd accepted that diagnosis and stopped investigating, she'd still be in that fog.
What does it mean that Empaveli is the first real treatment?
For decades, doctors were essentially managing decline. They could slow things down a little, but the disease always won. Now there's a medication that actually stops it and puts patients into remission. That's the difference between a life sentence and a life.
Does her story change anything about how rare diseases get diagnosed?
It highlights the problem: rare diseases are invisible to most doctors because they see so few cases. You need specialists who stay curious, who don't accept the easy answer. And you need patients willing to advocate for themselves when something doesn't feel right.